The Arizona Cancer Center is recruiting for a smoking-cessation vaccine research study up to 50 people, ages 18 to 65, who smoke and are ready to quit.
Arizona Cancer Center researcher Scott Leischow, PhD, is the local lead for a nationwide clinical trial for an investigational vaccine to treat nicotine addiction and help prevent smoking relapse.
“Smoking cessation is often the most difficult experience in the life of a smoker,” Dr. Leischow said. “This study will explore a novel approach, a nicotine vaccine, to help more smokers quit.”
The study is being funded in part by a $10 million grant from the U.S. National Institute on Drug Abuse, part of the National Institutes of Health.
The investigational vaccine, NicVAX® (Nicotine Conjugate Vaccine), is manufactured by Nabi Biopharmaceuticals of Rockville, Md. This Phase III double-blind, placebo-controlled research study will enroll approximately 1,000 participants.
For more information on this research study or to find out if you are qualified, call (520) 626-1900.
E-mail this page
